AnesthesiamemsorbNCT03014336
A New and Innovative Method for CO2 Removal in Anesthetic Circuits
A study testing memsorb in people with Anesthesia, run by DMF Medical Incorporated at 2 sites in Canada.
Trial summary
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Anesthesia
- What is being tested?
- memsorb
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 286 participants
- Where
- 2 sitesCanada
- Study dates
- 20 Mar 2017to 24 Jul 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
- English-speaking patients
Who cannot join
- Self-reported as pregnant
- American Society of Anesthesiologists Physical Status Class IV (high risk patient)
- Patients scheduled for emergency surgery
- Documented respiratory disease, including COPD and severe asthma
- Documented elevated pressure in the brain (intra cranial pressure, ICP)
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
Queen Elizabeth II HSC, Halifax Infirmary Site
Halifax, Nova Scotia, B3H 3A7
McGill University Health Centre
Montreal, Quebec, H4A 3J1
About this study
Official title: A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
Read the detailed description
DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.
memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.
This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.
memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.
- Conditions
- Anesthesia
- Being tested
- memsorb
- Keywords
- co2 removal, anesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
memsorbDevice
memsorb is a CO2 filter replacing current chemical CO2 absorbers
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Patients receive standard care with a standard CO2 absorber and agree to include their data in the study. |
| memsorb | Experimental | Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study. Receives: Device: memsorb |
What is being measured
The primary outcome is the main question the study is designed to answer.
End-tidal CO2 Concentration (%)
The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure.
Measured: From the start to the end of the intra-operative period for each participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2017 (estimated)
- Study start20 Mar 2017
- Primary completion10 May 2022
- Study completion24 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for AnesthesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 286 participants (actual)
Sponsor and investigators
- Lead sponsor
- DMF Medical Incorporated
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Orlando Hung, MD, Principal investigator, Nova Scotia Health Authority
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03014336
- Sponsor's protocol ID
- DMF-CLIN-16-01
- Acronym
- memsorb
- Status last verified
- Feb 2026
- First submitted
- 12 Oct 2016
- Last updated
- 23 Feb 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate
- ClinicalTrials.gov ID
- NCT03014336
- Acronym / sponsor ID
- memsorb / DMF-CLIN-16-01
- Conditions
- Anesthesia
- Keywords
- co2 removal, anesthesia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 286 participants (actual)
- Lead sponsor
- DMF Medical IncorporatedIndustry (pharma, biotech, devices)
- Study start
- 20 Mar 2017 (actual)
- Primary completion
- 10 May 2022 (actual)
- Study completion
- 24 Jul 2024 (actual)
- First posted
- 9 Jan 2017 (estimated)
- Results
- Posted 23 Feb 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
Detailed description
DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.
memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.
This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.
memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Patients receive standard care with a standard CO2 absorber and agree to include their data in the study. |
| memsorb | Experimental | Device: memsorbPatients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
- English-speaking patients
Key exclusion criteria (5 listed)
- Self-reported as pregnant
- American Society of Anesthesiologists Physical Status Class IV (high risk patient)
- Patients scheduled for emergency surgery
- Documented respiratory disease, including COPD and severe asthma
- Documented elevated pressure in the brain (intra cranial pressure, ICP)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| memsorbmemsorb is a CO2 filter replacing current chemical CO2 absorbers | Device | memsorb |
Primary outcome
End-tidal CO2 Concentration (%)
Time frame: From the start to the end of the intra-operative period for each participant
The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Anesthesia
Recruiting
NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia
Intraoperative Analgesia
RecruitingObservational study
Prevalence of Pain During Cesarean Section
Cesarean Birth
RecruitingObservational study
Pulse Wave Transit Time After Infraclavicular Block
Infraclavicular Brachial Plexus Block
RecruitingPhase 4
Propofol-Ketamine Versus Sevoflurane for Laryngeal Mask Anesthesia in Pediatric Cardiac Catheterization
Propofol, Ketamine
Recruiting
Lateral QL Block vs Intrathecal Morphine for Cesarean Section
Anesthesia, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Orlando Hung, MD principal investigator
Nova Scotia Health Authority
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing memsorb in people with Anesthesia, run by DMF Medical Incorporated at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Feb 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
End-tidal CO2 Concentration (%) (time frame: From the start to the end of the intra-operative period for each participant). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.